Clinical and pathological features of second primary neoplasms arising in head and neck reconstructive skin flaps.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 07 2023
11 07 2023
Historique:
received:
20
12
2022
accepted:
03
07
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
The incidence of second primary neoplasms arising in the skin reconstructive flap (SNAF) is increasing because of the increase in head and neck flap reconstruction and cancer survival. Prognosis, optimal treatment, and their clinicopathological-genetic features are under debate and are difficult to diagnose. We retrospectively reviewed SNAFs based on a single center's experience over 20 years. Medical records and specimens of 21 patients with SNAF who underwent biopsies between April 2000 and April 2020 at our institute were retrospectively analyzed. Definite squamous cell carcinoma and the remaining neoplastic lesions were subclassified as flap cancer (FC) and precancerous lesions (PLs), respectively. Immunohistochemical studies focused on p53 and p16. TP53 sequencing was conducted using next-generation sequencing. Seven and 14 patients had definite FC and PL, respectively. The mean number of biopsies/latency intervals was 2.0 times/114 months and 2.5 times/108 months for FC and PL, respectively. All lesions were grossly exophytic and accompanied by inflamed stroma. In FC and PL, the incidences of altered p53 types were 43% and 29%, respectively, and those of positive p16 stains were 57% and 64%, respectively. Mutation of TP53 in FC and PL were 17% and 29%, respectively. All except one patient with FC under long-term immunosuppressive therapy survived in this study. SNAFs are grossly exophytic tumors with an inflammatory background and show a relatively low altered p53 and TP53 rate and a high p16 positivity rate. They are slow-growing neoplasms with good prognoses. Diagnosis is often difficult; therefore, repeated or excisional biopsy of the lesion may be desirable.
Identifiants
pubmed: 37433786
doi: 10.1038/s41598-023-38122-9
pii: 10.1038/s41598-023-38122-9
pmc: PMC10336017
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11214Informations de copyright
© 2023. The Author(s).
Références
Int Wound J. 2022 May;19(4):895-909
pubmed: 34535972
Head Neck. 1994 Jan-Feb;16(1):79-82
pubmed: 8125793
Oral Oncol. 2007 Mar;43(3):263-71
pubmed: 16920383
Eur Arch Otorhinolaryngol. 2011 Jan;268(1):147-50
pubmed: 20976462
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Dec;112(6):e54-8
pubmed: 21856189
Cancer Sci. 2012 Feb;103(2):161-8
pubmed: 22070675
Burns. 2005 Jun;31(4):403-13
pubmed: 15896501
Head Neck Pathol. 2019 Dec;13(4):643-647
pubmed: 30888639
Histopathology. 2011 Feb;58(3):361-7
pubmed: 21255069
Ann Surg Oncol. 2019 Dec;26(Suppl 3):614-615
pubmed: 31098781
J Oral Pathol Med. 2004 Jul;33(6):317-22
pubmed: 15200478
J Oral Maxillofac Surg. 2000 May;58(5):495-9
pubmed: 10800904
Int J Surg Case Rep. 2013;4(8):731-4
pubmed: 23835250
Eur Arch Otorhinolaryngol. 2008 Jul;265(7):831-5
pubmed: 18004582
Ann Ital Chir. 2016 Feb 04;87(ePub):
pubmed: 27131477
Br J Plast Surg. 1992 Jan;45(1):70-1
pubmed: 1737215
J Laryngol Otol. 1990 Oct;104(10):827-8
pubmed: 2246588
Dermatol Surg. 1998 May;24(5):561-5
pubmed: 9598012
Yonago Acta Med. 2011 Mar;54(1):33-6
pubmed: 24031126
ORL J Otorhinolaryngol Relat Spec. 1998 May-Jun;60(3):170-3
pubmed: 9579363
Ann Diagn Pathol. 2012 Apr;16(2):91-9
pubmed: 22197546
Otolaryngol Head Neck Surg. 1985 Dec;93(6):754-8
pubmed: 3937097
Plast Reconstr Surg. 1965 Aug;36:173-84
pubmed: 14339173
Oral Oncol. 2021 Feb;113:105091
pubmed: 33249291
Ann Surg Oncol. 2019 Jul;26(7):2294-2303
pubmed: 30900104
J Oral Maxillofac Surg. 2013 Sep;71(9):1619-25
pubmed: 23611605
Head Neck. 2002 Jan;24(1):87-90
pubmed: 11774408